Cadila Healthcare, a Rs 1400-crore plus Ahmedabad based pharma giant, has achieved better performance during the third quarter ended December 2007. The company's consolidated net profit increased by 8.4 per cent to Rs 50.6 crore from Rs 46.7 crore in the corresponding period of last year. Its total income increased to Rs 579.6 crore from Rs 472.4 crore, a growth of 22.7 per cent. The income growth was mainly driven by a growth of 47 per cent in formulation exports. The company's consumer business was up by 27 per cent.

During the quarter, Cadial's subsidiaries in France and US registered a strong performance. Zydus France SAS, which currently markets over 100 generic presentations, registered a healthy 31 per cent growth in its generics business. Continuing with supplies from India to France, the group now manufactures 15 products in India, of which 4 are new products and 11 are site transfers. The company filed two dossiers for new products and four site transfer applications with the French regulatory authority AFSSAPS.

Its US sales increased by 47 per cent to Rs 57 crore. The group filed four more ANDAs and two additional DMFs during the quarter ended December 2007, taking the total to 70 ANDA filings and 57 DMFs. The group has received 32 product approvals so far. Besides this, the company signed three new contracts for contract manufacturing with international companies. Cadila has now a total of 26 contracts with peak revenue potential of US $40.5 million.